Ottimo Pharma

Our CEO, David Epstein, and Head of Development, Mehdi Shahidi, were at the Jefferies Biotech on the Beach Summit yesterday to discuss “Revolution in Oncology: Where does PD-1 X VEGF Drug Class Fit In”.  With our first in class, dual paratopic PD-1/VEGFR2 antibody, Jankistomig, we at Ottimo Pharma dare to ask WHAT IF our bispecific antibody design paradigm could elevate the I/O standard of care! #OttimoPharma #Oncology #ElevateStandardofCare

 📢 Ottimo Pharma strengthens its leadership team with the appointments of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn as Senior Vice President of Clinical Development.   With over 20 years of experience, Rob brings deep expertise in #immuno-oncology, #preclinical research, and translational science, having successfully led multiple #IND applications. Kathy brings decades of experience in #oncology clinical development, with a proven track record of bringing novel cancer treatments from early-stage research into clinical trials.   These strategic appointments come as Ottimo accelerates its effort to bring transformative cancer therapies to patients.   #Jankistomig, our first-in-class PD1/VEGFR2 dual pathway antibody, is on track for IND clearance in late 2025.   #OttimoPharma #Oncology #Appointments   👇Find the full press release in the comments below.

 📢 Ottimo Pharma strengthens its leadership team with the appointments of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences and Katherine Bell-McGuinn as Senior Vice President of Clinical Development.   With over 20 years of experience, Rob brings deep expertise in #immuno-oncology, #preclinical research, and translational science, having successfully led multiple #IND applications. Kathy brings decades of experience in #oncology clinical development, with a proven track record of bringing novel cancer treatments from early-stage research into clinical trials.   These strategic appointments come as Ottimo accelerates its effort to bring transformative cancer therapies to patients.   #Jankistomig, our first-in-class PD1/VEGFR2 dual pathway antibody, is on track for IND clearance in late 2025.   #OttimoPharma #Oncology #Appointments   👇Find the full press release in the comments below.

Our CEO, David Epstein, recently spoke to Citeline’s Scrip about his predictions on ‘Therapeutic Area Advances’ in oncology for the year ahead.   In conversation with Eleanor Malone, David shared a hopeful outlook on the future of cancer treatment: “three classes of anticancer medicines will make still bigger strides: ADCs, bispecifics and bifunctional antibodies, as they offer more tumor targeted therapy than traditional mainstays…efficacy will increase, therapeutic windows will widen and patients will stay on medicines longer thus living longer, better lives.”   Read more: https://lnkd.in/dSyX8Mmu   #ScripAsks2025 #oncology #cancerresearch

Ottimo is #hiring a new Translational Lead for Early Development – Oncology in United States.

We’re thrilled to see our $140 million Series A financing featured in the Financial Times!   A big thank you to Hannah Kuchler for covering this milestone as we advance our mission to bring first-in-class bifunctional medicines to people living with cancer.

To coincide with our over $140M Series A financing, Ottimo Pharma is building a world-class team to progress our mission.   We’re excited to welcome Rick Anderson as SVP Finance (formerly Seagen), Spencer Fisk as Chief Technical and Quality Officer (formerly Novartis, Rubius Therapeutics), and ling zeng as General Counsel and EVP of Execution (formerly Dicerna, Omega Therapeutics).   Their extensive experience and proven track records will be instrumental as we prepare for our first IND filing in late 2025 and scale our efforts to deliver first-in-class bifunctional medicines to cancer patients.   For further details, find the full press release linked in the comments below.   #OttimoPharma #Financing #Biotech #Oncology #CancerResearch

Exciting News from Ottimo Pharma! 🎉   We’re pleased to announce the successful completion of our Series A financing round, raising over $140 million to accelerate the development of our first-in-class bifunctional medicines for cancer treatment.   The round was led by OrbiMed, Avoro Capital, and Samsara BioCapital, with participation from RTW Investments, LP, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences Private Capital, The Invus Group, and our founding investor Medicxi.   Alongside this milestone, we’re thrilled to welcome Rick Anderson (SVP Finance), Spencer Fisk (Chief Technical and Quality Officer), and ling zeng (General Counsel and EVP of Execution) to the Ottimo Pharma leadership team. Their expertise and proven track records will be instrumental as we advance our pipeline, led by Jankistomig, a PD1/VEGFR2 bifunctional antibody. IND-enabling studies for Jankistomig are already underway, with a planned IND filing in late 2025.   Stay tuned for more updates as we advance towards clinical trials!   For more details, the full press release is linked in the comments below.   #OttimoPharma #Financing #Biotech #Oncology #CancerResearch

Ottimo Pharma has officially launched, with backing from Medicxi and the appointment of an exceptional management team.   Read the full press release 👉 www.ottimopharma.com   #OttimoPharma #Biotech #Pharma #CancerResearch #Immunotherapy

📢 Exciting news from Ottimo Pharma! 📢 We have officially launched, with backing from Medicxi and the appointment of an exceptional management team. Leading the charge is David Epstein, who joins as Chair and Chief Executive Officer. He is joined by Mehdi Shahidi, Ottimo’s Head of Development and Chief Medical Officer, and James Sabry, who joins as Vice-Chair of the Board. Ottimo is focused on advancing Jankistomig, our groundbreaking PD1/VEGFR2 bi-functional antibody designed to change the face of cancer immunotherapy by targeting both immune checkpoint inhibition and angiogenesis. With this innovative approach, we aim to deliver new hope to patients with solid tumors. Preclinical work is already underway, and we expect to enter the clinic in 2025. Make sure you’re following Ottimo Pharma on LinkedIn to stay up to date as we work to bring this game-changing therapy to patients! 👉 For more details, read the full press release linked in the comments below. #OttimoPharma #Biotech #Pharma #CancerResearch #Immunotherapy